Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Helix BioPharma Corp

HBP.TO ✓ COMPLIANT ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$1.30

▲ +0.00%

Market Cap $99.53M · Vol 3.31K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$99.53M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

38.37

Momentum

Beta

-0.41

vs Market

52W High

$3.91

66.36% below

52W Low

$0.80

67.12% above

Volume

3.31K

Avg 2.41K

P/B

5.09

Price-to-book

ROE

N/A

Return on equity

Free Float

58.10%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Helix BioPharma Corp (HBP.TO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HBP.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.74%

+12.50%

+17.65%

-13.46%

YTD

-24.05%

+24.14%

+48.12%

-54.43%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-3,757,580.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-51.30% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	76.38M

Technical Indicators

50-Day SMA	$1.18
200-Day SMA	$1.35
RSI (14)	38.37
Beta	-0.41
52-Week High	$3.91
52-Week Low	$0.80

Volume Today	3.31K
Avg Daily Volume (30D)	2.41K
Relative Volume	1.37x
Volatility (10D)	94.29
Volatility (30D)	66.10
Free Float	58.10%

Analyst Consensus

N/A

Current Price $1.30

Mean Target N/A

52W Low$0.80 52W High$3.91

Current

Target

$0.80 $3.91

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG001S66SP8

ISINCA4229102088

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.82% RVMD Revolution Medicines Inc -1.29% ONC BeOne Medicines AG -1.89% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +3.62%

Company Profile

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.